Ligustrazine reverts anthracycline chemotherapy resistance of human breast cancer by inhibiting JAK2/STAT3 signaling and decreasing fibrinogen gamma chain (FGG) expression.

Liu, Yu-Lin; Yan, Ze-Xuan; Xia, Yu; Xie, Xiao-Ye; Zhou, Kai; Xu, Li-Li; Shi, Yan-Long; Wang, Qiang; Bi, Jing-Wang

Liu, Yu-Lin; Yan, Ze-Xuan; Xia, Yu; Xie, Xiao-Ye; Zhou, Kai; Xu, Li-Li; Shi, Yan-Long; Wang, Qiang; Bi, Jing-Wang.

Afiliação

Liu YL; Clinical Laboratory, Navy 971 Hospital of PLA Qingdao 266071, China.
Yan ZX; Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University Chongqing 400038, China.
Xia Y; Clinical Laboratory, Navy 971 Hospital of PLA Qingdao 266071, China.
Xie XY; Department of Oncology, 960 Hospital of PLA Jinan 250031, China.
Zhou K; Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Army Medical University Chongqing 400038, China.
Xu LL; Clinical Laboratory, Navy 971 Hospital of PLA Qingdao 266071, China.
Shi YL; Department of Oncology, 960 Hospital of PLA Jinan 250031, China.
Wang Q; Clinical Laboratory, Navy 971 Hospital of PLA Qingdao 266071, China.
Bi JW; Department of Oncology, 960 Hospital of PLA Jinan 250031, China.

Am J Cancer Res ; 10(3): 939-952, 2020.

Article em En | MEDLINE | ID: mdl-32266101

Palavras-chave

JAK2/STAT3 pathway; Ligustrazine; anthracycline; breast cancer; chemotherapy resistance; fibrinogen gamma chain

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Am J Cancer Res Ano de publicação: 2020 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google